INMIND: A PHASE 3 STUDY OF TAFASITAMAB + LENALIDOMIDE AND RITUXIMAB VS PLACEBO + LENALIDOMIDE AND RITUXIMAB FOR RELAPSED/REFRACTORY FOLLICULAR OR MARGINAL ZONE LYMPHOMA
Hübel, K., Scholz, C. W., Luminari, S., Salar, A., Wahlin, B. E., Gopal, A. K., Bonnet, C., Trneny, M., Paneesha, S., Manzke, O., Seguy, F., Li, D., Sehn, L. H.
Published in Hematological oncology (01.06.2021)
Published in Hematological oncology (01.06.2021)
Get full text
Journal Article
617MO Safety and tolerability of INCB123667, a selective CDK2 inhibitor, in patients (pts) with advanced solid tumors: A phase I study
Simonelli, M., Lorusso, D., Homicsko, K., Seguy, F., Kinder, M., Liu, Q., Croft, E., Kitano, S.
Published in Annals of oncology (01.09.2024)
Published in Annals of oncology (01.09.2024)
Get full text
Journal Article
A phase 3 study to evaluate the efficacy and safety of tafasitamab plus lenalidomide and rituximab versus placebo plus lenalidomide and rituximab in patients with relapsed/refractory (R/R) follicular lymphoma (FL) or marginal zone lymphoma (MZL)
Sehn, Laurie Helen, Scholz, Christian W, Luminari, Stefano, Salar, Antonio, Wahlin, Bjorn E., Gopal, Ajay K., Bonnet, Christophe Marc, Paneesha, Shankara, Manzke, Oliver, Seguy, Francis, Li, Di, Hübel, Kai
Published in JOURNAL OF CLINICAL ONCOLOGY (20.05.2021)
Published in JOURNAL OF CLINICAL ONCOLOGY (20.05.2021)
Get full text
Journal Article
Conference Proceeding
117 A PHASE 3 STUDY OF LENALIDOMIDE VERSUS PLACEBO IN RBC TRANSFUSION-DEPENDENT (TD) PATIENTS WITH LOWER-RISK MDS WITHOUT DEL(5Q) UNRESPONSIVE OR REFRACTORY TO ERYTHROPOIESIS-STIMULATING AGENTS (ESAS)
Santini, V, Almeida, A, Giagounidis, A, Gröpper, S, Jonasova, A, Vey, N, Mufti, G.J, Buckstein, R, Mittelman, M, Platzbecker, U, Shpilberg, O, Ram, R, del Canizo, C, Gattermann, N, Ozawa, K, Risueno, A, MacBeth, K.J, Zhong, J, Séguy, F, Hoenekopp, A, Beach, C.L, Fenaux, P
Published in Leukemia research (01.04.2015)
Published in Leukemia research (01.04.2015)
Get full text
Journal Article
inMIND: A Phase 3 Study of Tafasitamab plus Lenalidomide Add-On to Rituximab vs Placebo plus Lenalidomide Add-On to Rituximab for Relapsed/Refractory (R/R) Follicular Lymphoma (FL) or Marginal Zone Lymphoma (MZL)
Sehn, LH, Scholz, CW, Luminari, S, Salar, A, Wahlin, BE, Gopal, AK, Bonnet, C, Trneny, M, Paneesha, S, Manzke, O, Seguy, F, Li, D, Hubel, K
Published in CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2021)
Get full text
Published in CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2021)
Conference Proceeding
Phase I Pharmacological and Bioavailability Study of Oral Diflomotecan (BN80915), a Novel E-Ring-modified Camptothecin Analogue in Adults with Solid Tumors
GELDERBLOM, Hans, SALAZAR, Ramon, PRINCIPE, Paola, TWELVES, Chris, VERWEIJ, Jaap, PENTHEROUDAKIS, George, DE JONGE, Maja J. A, DEVLIN, Martin, VAN HOOIJE, Christel, SEGUY, Francis, OBACH, Rosendo, PRUNONOSA, Joan
Published in Clinical cancer research (15.09.2003)
Get full text
Published in Clinical cancer research (15.09.2003)
Journal Article
La micro vascularisation de la surface osseuse : étude préliminaire expérimentale in vivo chez le lapin
Seguy, F., Delfosse, C., Penel, G., Libersa, P., Hardouin, P., Leroy, G.
Published in Morphologie (01.07.2004)
Published in Morphologie (01.07.2004)
Get full text
Journal Article